2023
Idiopathic myointimal hyperplasia of the mesenteric veins: A systematic review and individual patient data regression analysis
Rozner R, Gisriel S, Damianos J, Grimshaw A, Rizwan R, Nawaz A, Chan K, Wan D, Pantel H, Bhutta A, Fenster M, Brandt L, Barbieri A, Robert M, Feuerstadt P, Li D. Idiopathic myointimal hyperplasia of the mesenteric veins: A systematic review and individual patient data regression analysis. Journal Of Gastroenterology And Hepatology 2023, 38: 1040-1046. PMID: 37086041, DOI: 10.1111/jgh.16193.Peer-Reviewed Original ResearchConceptsIdiopathic myointimal hyperplasiaColonic ischemiaMesenteric veinRectal bleedingRectal involvementMyointimal hyperplasiaSystematic reviewYounger ageMultivariate logistic regression analysisCurative surgical resectionInferior mesenteric veinPre-surgical identificationLogistic regression analysisRegression analysisIschemic colitisAbdominal painMucosal ulcerationEndoscopic findingsSelect patientsSurgical resectionUncommon causeDiagnostic delaySurgical treatmentClinical featuresHospital records
2020
Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy
Tang T, Abu-Sbeih H, Ma W, Lu Y, Luo W, Foo W, Richards D, Halperin D, Ge P, Wang Y. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. Clinical Colorectal Cancer 2020, 19: e117-e123. PMID: 32284253, DOI: 10.1016/j.clcc.2020.03.002.Peer-Reviewed Original ResearchConceptsAbnormal endoscopic findingsAntiangiogenesis cancer therapyIntensive care unitAntiangiogenesis therapyACD symptomsAntimotility agentsEndoscopic findingsColonic perforationCare unitTertiary care cancer centerActive histologic inflammationRare adverse eventsCancer therapyEnterocolitis symptomsHistologic inflammationNonulcerative inflammationUnderlying malignancyGastrointestinal injuryGastrointestinal toxicityMucosal ulcerationUnderwent endoscopyAdverse eventsMedian durationMost patientsEndoscopic evaluationSmooth muscle tumors of the gastrointestinal tract: an analysis of prognostic features in 407 cases
Alpert L, Al-Sabti R, Graham RP, Pai RK, Gonzalez RS, Zhang X, Smith V, Wang HL, Westbrook L, Goldblum JR, Bakhshwin A, Shetty S, Klimstra DS, Shia J, Askan G, Robert ME, Thomas C, Frankel WL, Alsomali M, Hagen C, Mostafa ME, Feely MM, Assarzadegan N, Misdraji J, Shih AR, Agostini-Vulaj D, Meis JM, Tang S, Chatterjee D, Kang LI, Hart J, Lee SM, Smith T, Yantiss RK, Hissong EM, Gao ZH, Wu J, Resnick MB, Wu EY, Pai RK, Zhao L, Doyle LA, Chopra S, Panarelli NC, Hu S, Longacre TA, Raghavan SS, Lauwers GY, Ghayouri M, Cooper HS, Nagarathinam R, Bellizzi AM, Kakar S, Hosseini M, Rong J, Greenson JK, Lamps LW, Dong Z, Bronner MP. Smooth muscle tumors of the gastrointestinal tract: an analysis of prognostic features in 407 cases. Modern Pathology 2020, 33: 1410-1419. PMID: 32051556, PMCID: PMC8405135, DOI: 10.1038/s41379-020-0492-5.Peer-Reviewed Original ResearchConceptsSmooth muscle tumorsGastrointestinal smooth muscle tumorsMuscle tumorsPrognostic featuresSmall bowelGastrointestinal tractNon-progressive tumorsProgression-free survivalSlight female predominanceDisease-related deathKaplan-Meier plotsReceiver operator characteristic analysisSoft tissue pathologistsPotential prognostic featuresOperator characteristic analysisMucosal ulcerationSerosal involvementFemale predominanceLocal recurrenceMargin statusPathologic featuresTumor sizeLarge tumorsEsophageal tumorsTumor necrosis
2018
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
Abu-Sbeih H, Ali F, Alsaadi D, Jennings J, Luo W, Gong Z, Richards D, Charabaty A, Wang Y. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study. Journal For ImmunoTherapy Of Cancer 2018, 6: 142. PMID: 30518410, PMCID: PMC6280383, DOI: 10.1186/s40425-018-0461-4.Peer-Reviewed Original ResearchConceptsMean durationImmune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisImmune checkpoint inhibitor treatmentAbnormal endoscopic findingsActive histologic inflammationCheckpoint inhibitor treatmentClinical success rateRetrospective case seriesGood safety profileFeatures of chronicityMulti-center studyEndoscopic remissionHistologic inflammationHistologic remissionICI therapyNonulcerative inflammationSteroid therapyVedolizumab infusionsVedolizumab therapyClinical remissionMicroscopic colitisMucosal ulcerationSystemic immunosuppressionAdvanced malignanciesImportance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
Abu-Sbeih H, Ali F, Luo W, Qiao W, Raju G, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. Journal For ImmunoTherapy Of Cancer 2018, 6: 95. PMID: 30253811, PMCID: PMC6156850, DOI: 10.1186/s40425-018-0411-1.Peer-Reviewed Original ResearchConceptsEndoscopic featuresClinical outcomesHistologic featuresGrade 3Immune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisLogistic regressionActive histologic inflammationActive histological inflammationBackgroundImmune checkpoint inhibitorsExtensive colonic involvementMore frequent hospitalizationsMore recurrent symptomsHigh-risk featuresMultivariate logistic regressionSuch adverse eventsTime of onsetHistologic inflammationICPI treatmentCheckpoint inhibitorsColonic involvementEndoscopic inflammationHistological inflammationMucosal ulcerationRecurrent symptoms
2017
Lack of Effect of Murine Astrovirus Infection on Dextran Sulfate-induced Colitis in NLRP3-deficient Mice.
Compton SR, Booth CJ, Macy JD. Lack of Effect of Murine Astrovirus Infection on Dextran Sulfate-induced Colitis in NLRP3-deficient Mice. Journal Of The American Association For Laboratory Animal Science 2017, 67: 400-406. PMID: 28935001, PMCID: PMC5621567.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAstroviridaeAstroviridae InfectionsColitisColonDextran SulfateDisease Models, AnimalFemaleGastrointestinal MicrobiomeInflammasomesMaleMiceMice, Inbred C57BLNLR Family, Pyrin Domain-Containing 3 ProteinRandom AllocationReal-Time Polymerase Chain ReactionReproducibility of ResultsRodent DiseasesRodentiaConceptsColitis modelInflammatory bowel disease researchNOD-like receptor 3Induced colitis modelSeverity of colitisDextran sodium sulfateDSS colitis modelNLRP3-deficient miceDefective inflammasome activationLack of effectMucosal ulcerationIntestinal inflammationHistopathologic changesIntestinal permeabilityAstrovirus infectionFemale miceClinical signsDeficient miceNLRP3 mutationsClinical diseaseInflammasome activationGastrointestinal tractMurine astrovirusIntestinal bacteriaIntestinal epithelium
2016
Colonic vasculopathy and perforation in the initial presentation of adult dermatomyositis in a patient with improving muscle weakness
Kibbi N, Bekui A, Buckley LM. Colonic vasculopathy and perforation in the initial presentation of adult dermatomyositis in a patient with improving muscle weakness. BMJ Case Reports 2016, 2016: bcr2015213460. PMID: 26759443, PMCID: PMC4716365, DOI: 10.1136/bcr-2015-213460.Peer-Reviewed Original ResearchConceptsAdult dermatomyositisMuscle weaknessDose of IVIGProminent lymphoplasmacytic infiltrationProximal muscle weaknessConnective tissue diseaseBowel habitsEmergent colectomyGI manifestationsPrednisone therapyAbdominal painGastrointestinal perforationInitial manifestationMucosal ulcerationFatal complicationLymphoplasmacytic infiltrationCutaneous inflammationInitial presentationTissue diseaseMuscle strengthVenous occlusionMuscle biopsyDermatomyositisArterial hyperplasiaSerological studies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply